Non-immunogenic staphylokinase in patients with massive intermediate-high risk pulmonary embolism: protocol of the FORPE-2 multicenter, double-blind, randomized, placebo-controlled trial
Authors:
- S. N. TereshchenkoSTS. N. Tereshchenko
- E. B. YarovayaE. B. Yarovaya
- S. G. LeontievSLS. G. Leontiev
- I. S. YavelovIYI. S. Yavelov
- R. M. ShakhnovichRSR. M. Shakhnovich
- A. D. ErlikhAEA. D. Erlikh
- D. V. DuplyakovD. V. Duplyakov
- V. A. KutsenkoVKV. A. Kutsenko
- O. E. IvlevOIO. E. Ivlev
- A. G. SoplenkovaASA. G. Soplenkova
- A. M. SemenovASA. M. Semenov
Open Access
- 15 March 2025
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (2) , 6291
Abstract
Aim. To evaluate the efficacy and safety of single bolus administration of non-immunogenic staphylokinase in comparison with placebo in patients with intermediatehigh risk pulmonary embolism (PE) within the FORPE-2 clinical trial.Material and methods. Non-immunogenic staphylokinase has high thrombolytic activity and fibrin selectivity. The FORPE-2 clinical trial has a multicenter, doubleblind, randomized, placebo-controlled design. In clinical sites, patients (486 in total, with a possible 10% dropout rate) with confirmed PE and evidence of right ventricular dysfunction based on computed tomography pulmonary angiography and an increased risk of hemodynamic instability (intermediate-high-risk PE) will be equally randomized into two groups to receive non-immunogenic staphylokinase or placebo. The study protocol provides inclusion and exclusion criteria, calculation of the required patient sample size, and the study plan. The primary efficacy endpoint will be a composite of all-cause mortality, hemodynamic collapse, and recurrent PE within 30 days of randomization. Safety endpoints will be hemorrhagic stroke during hospitalization and BARC type 3 and 5 bleeding types.Results. The study will provide data on the efficacy and safety of non-immunogenic staphylokinase in patients with intermediate-high risk PE. A report will be compiled with individual data and statistical analysis of the results.Keywords
This publication has 18 references indexed in Scilit:
- Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPEJournal of Thrombosis and Haemostasis, 2024
- Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trialThrombosis and Haemostasis, 2021
- Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trialThe Lancet Neurology, 2021
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)European Respiratory Journal, 2019
- Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trialsEuropean Respiratory Journal, 2018
- Management of Pulmonary EmbolismJACC, 2016
- Fibrinolysis for Patients with Intermediate-Risk Pulmonary EmbolismNew England Journal of Medicine, 2014
- Acute Pulmonary EmbolismNew England Journal of Medicine, 2008
- Prospective validation of the Pulmonary Embolism Severity IndexThrombosis and Haemostasis, 2008
- Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary EmbolismNew England Journal of Medicine, 2002